Nature Communications (Nov 2022)
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
- I’ah Donovan-Banfield,
- Rebekah Penrice-Randal,
- Hannah Goldswain,
- Aleksandra M. Rzeszutek,
- Jack Pilgrim,
- Katie Bullock,
- Geoffrey Saunders,
- Josh Northey,
- Xiaofeng Dong,
- Yan Ryan,
- Helen Reynolds,
- Michelle Tetlow,
- Lauren E. Walker,
- Richard FitzGerald,
- Colin Hale,
- Rebecca Lyon,
- Christie Woods,
- Shazaad Ahmad,
- Dennis Hadjiyiannakis,
- Jimstan Periselneris,
- Emma Knox,
- Calley Middleton,
- Lara Lavelle-Langham,
- Victoria Shaw,
- William Greenhalf,
- Thomas Edwards,
- David G. Lalloo,
- Christopher J. Edwards,
- Alistair C. Darby,
- Miles W. Carroll,
- Gareth Griffiths,
- Saye H. Khoo,
- Julian A. Hiscox,
- Thomas Fletcher
Affiliations
- I’ah Donovan-Banfield
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Rebekah Penrice-Randal
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Hannah Goldswain
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Aleksandra M. Rzeszutek
- Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Jack Pilgrim
- Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Katie Bullock
- GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Geoffrey Saunders
- Southampton Clinical Trials Unit, University of Southampton
- Josh Northey
- Southampton Clinical Trials Unit, University of Southampton
- Xiaofeng Dong
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Yan Ryan
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Helen Reynolds
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Michelle Tetlow
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Lauren E. Walker
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Richard FitzGerald
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Colin Hale
- NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust
- Rebecca Lyon
- NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust
- Christie Woods
- NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust
- Shazaad Ahmad
- NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust
- Dennis Hadjiyiannakis
- NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust
- Jimstan Periselneris
- NIHR Kings Clinical Research Facility, King’s College Hospital NHS Foundation Trust
- Emma Knox
- Southampton Clinical Trials Unit, University of Southampton
- Calley Middleton
- Southampton Clinical Trials Unit, University of Southampton
- Lara Lavelle-Langham
- GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Victoria Shaw
- GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- William Greenhalf
- GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Thomas Edwards
- Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine
- David G. Lalloo
- Liverpool School of Tropical Medicine
- Christopher J. Edwards
- Human Development and Health School, University of Southampton
- Alistair C. Darby
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Miles W. Carroll
- NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
- Gareth Griffiths
- Southampton Clinical Trials Unit, University of Southampton
- Saye H. Khoo
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
- Julian A. Hiscox
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Thomas Fletcher
- NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
- DOI
- https://doi.org/10.1038/s41467-022-34839-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 9
Abstract
Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. No treatment-associated SARS-CoV-2 mutations were identified.
